Sign In
Buy IONS
$73.82
+0.85 (+1.16%)
At Close: Jun 03, 2026
Exploring Analyst Estimates for Ionis Pharmaceuticals (IONS) Q4 Earnings, Beyond Revenue and EPS
10:15am, Friday, 20'th Feb 2026
Besides Wall Street's top-and-bottom-line estimates for Ionis Pharmaceuticals (IONS), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared
Ionis to present at upcoming investor conferences
07:05am, Thursday, 19'th Feb 2026
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: Oppenheimer 36th
7,764 Shares in Ionis Pharmaceuticals, Inc. $IONS Acquired by Stratos Wealth Partners LTD.
03:26am, Thursday, 19'th Feb 2026
Stratos Wealth Partners LTD. bought a new stake in Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commiss
Ionis updates time for fourth quarter and full year 2025 financial results webcast
02:58pm, Tuesday, 17'th Feb 2026
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced a change in the start time for its fourth quarter and full year 2025 financial results webcast. The live w
Brett Monia Sells 29,430 Shares of Ionis Pharmaceuticals (NASDAQ:IONS) Stock
04:07am, Thursday, 12'th Feb 2026
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS - Get Free Report) CEO Brett Monia sold 29,430 shares of the stock in a transaction dated Friday, February 6th. The stock was sold at an average price of $85.
Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
11:02am, Wednesday, 11'th Feb 2026
Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ionis to hold fourth quarter and full year 2025 financial results webcast
07:05am, Wednesday, 11'th Feb 2026
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, February 25 at 11:30 a.m. Eastern Time to discuss its fourt
C Frank Bennett Sells 85,089 Shares of Ionis Pharmaceuticals (NASDAQ:IONS) Stock
04:21am, Friday, 06'th Feb 2026
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS - Get Free Report) EVP C Frank Bennett sold 85,089 shares of Ionis Pharmaceuticals stock in a transaction on Monday, February 2nd. The stock was sold at an av
Tweedy Browne's Strategic Moves: Significant Increase in CNH Industrial NV
12:00pm, Tuesday, 03'rd Feb 2026
Insight into Tweedy Browne (Trades, Portfolio)'s Fourth Quarter 2025 13F Filing Tweedy Browne (Trades, Portfolio) recently submitted its 13F filing for the fou
Ionis Pharmaceuticals (NASDAQ:IONS) EVP Eugene Schneider Sells 6,179 Shares
05:04am, Tuesday, 03'rd Feb 2026
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS - Get Free Report) EVP Eugene Schneider sold 6,179 shares of the stock in a transaction that occurred on Friday, January 30th. The stock was sold at an averag
Ionis Pharmaceuticals (NASDAQ:IONS) EVP Brian Birchler Sells 6,179 Shares of Stock
05:04am, Tuesday, 03'rd Feb 2026
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS - Get Free Report) EVP Brian Birchler sold 6,179 shares of the business's stock in a transaction dated Friday, January 30th. The stock was sold at an average
Ionis Pharmaceuticals (NASDAQ:IONS) EVP Eric Swayze Sells 6,179 Shares
05:04am, Tuesday, 03'rd Feb 2026
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS - Get Free Report) EVP Eric Swayze sold 6,179 shares of the firm's stock in a transaction dated Friday, January 30th. The stock was sold at an average price o
BLB&B Advisors LLC Has $7.76 Million Stock Holdings in Ionis Pharmaceuticals, Inc. $IONS
03:44am, Sunday, 25'th Jan 2026
BLB&B Advisors LLC decreased its stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) by 21.7% during the undefined quarter, according to the company in its most recent 13F filing with the Se
Ionis' Dawnzera Gets EU Approval for Hereditary Angioedema
12:56pm, Thursday, 22'nd Jan 2026
IONS secures EU approval for Dawnzera in hereditary angioedema, after FDA clearance in the United States in August last year.
DAWNZERA™ (donidalorsen) approved in the European Union for hereditary angioedema (HAE)
07:00am, Wednesday, 21'st Jan 2026
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced that the European Commission (EC) has approved DAWNZERA™ (d
